# US 2019/0316081 A1 · Media and methods for expansion of pluripotent stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316081 A1
- Document ID: US20190316081A1
- Status: Published application
- Kind: A1
- Application number: 16/386,247
- Filed: 2019-04-16
- Published: 2019-10-17
- Earliest claimed: 2018-04-17
- Inventors: Yonatan Y. Lipsitz; Peter W. Zandstra
- Web page: https://patentgrep.com/patent/US20190316081A1

## CPC

- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C12N 5/0619: {Neurons}
- C12N 5/0657: {Cardiomyocytes; Heart cells}
- C12N 5/0676: {Pancreatic cells}
- C08L 5/02: Dextran; Derivatives thereof
- C12N 2500/30: Organic components
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/02: from embryonic cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

The present disclosure provides methods and reagents for culturing pluripotent stem cells. The method comprises a first step of culturing in a medium comprising inhibitors of GSK-3β, JNK, p38, PKC and Erk1/2, followed by a second step of culturing in a medium comprising inhibitors of GSK-3β, JNK, p38 and PKC, and not comprising an inhibitor of Erk1/2. The medium of the second step may also further comprise dextran sulfate. The pluripotent stem cells produced using the methods and reagents provided may also be differentiated into a cell type of interest. The methods and reagents provided in this disclosure offer robust and scalable technologies for manufacturing the quantities of cells anticipated to be required for widespread patient access.

## Claims

### Claim 1

A method for culturing a population of pluripotent stem cells, the method comprising:
culturing in a first medium comprising one or more inhibitors of GSK-3β, one or more inhibitors of JNK, one or more inhibitors of p38, one or more inhibitors of PKC and one or more inhibitors of Erk1/2; and
culturing in a second medium comprising one or more inhibitors of GSK-3β, one or more inhibitors of JNK, one or more inhibitors of p38 and one or more inhibitors of PKC, and not comprising an inhibitor of Erk1/2.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first and second media further comprise one or more of fibroblast growth factor 2; transforming growth factor-β1; a STAT3 activator; insulin; ascorbic acid; albumin; N2 supplement; non-essential amino acids; glutamine; and serum replacement.

### Claim 3 (depends on 1)

The method of claim 1, wherein the pluripotent stem cells cultured in the second medium are cultured as aggregates.

### Claim 4 (depends on 1)

The method of claim 1, wherein the second medium further comprises a polysulfated compound

### Claim 5 (depends on 1)

The method of claim 1, wherein the growth rate of the pluripotent stem cells cultured in the first medium and the second medium is increased compared to pluripotent stem cells not cultured in the first medium and the second medium.

### Claim 6

A method for culturing a population of pluripotent stem cells, the method comprising culturing the pluripotent stem cells in a medium comprising a polysulfated compound.

### Claim 7 (depends on 6)

The method of claim 6, wherein the pluripotent stem cells are cultured as aggregates.

### Claim 8 (depends on 6)

The method of claim 6, wherein the polysulfated compound is dextran sulfate.

### Claim 9 (depends on 6)

The method of claim 6, wherein the dextran sulfate has a molecular weight of about 4,000 Da to about 500,000 Da.

### Claim 10 (depends on 6)

The method of claim 6, the method further comprising culturing the pluripotent stem cell aggregates under dynamic suspension conditions.

### Claim 11 (depends on 6)

The method of claim 6, wherein the pluripotent stem cells are human.

### Claim 12 (depends on 6)

The method of claim 6, wherein the pluripotent stem cells are differentiated to cardiac progenitor cells, cardiac cells, pancreatic progenitor cells, pancreatic cells, ectoderm cells, neural cells, or hematopoietic cells.

### Claim 13

A medium for culturing pluripotent stem cell, the medium comprising a polysulfated compound.

### Claim 14 (depends on 13)

The medium of claim 13, wherein the pluripotent stem cells are cultured as aggregates.

### Claim 15 (depends on 13)

The medium of claim 13, wherein the polysulfated compound is dextran sulfate.

### Claim 16 (depends on 13)

The medium of claim 13, wherein the dextran sulfate has a molecular weight of about 4,000 Da to about 500,000 Da.

### Claim 17 (depends on 13)

The medium of claim 13, wherein the pluripotent stem cells are human.

### Claim 18 (depends on 6)

The method of claim 6 wherein the method generates at least one isolated single pluripotent stem cell.

### Claim 19 (depends on 13)

The medium of claim 13 wherein the medium generates at least one isolated single pluripotent stem cell.

### Claim 20 (depends on 18)

The method of claim 18 wherein the at least one isolated single pluripotent stem cell is human.
